Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3164
Shown on this page
12
Current sort
Recently updated
Location scope
San Antonio, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within San Antonio, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 805–816 of 3,164 matching trials in San Antonio, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Phase 1 Interventional

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

NCT06657144
View directory record Official record
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 3 Interventional

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

NCT03891446
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, Standard of Care
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
66
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 2 Interventional Results available

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

NCT06465368
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Barrington, Illinois • Crystal Lake, Illinois • Park Ridge, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Active, not recruiting Phase 2 Interventional

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

NCT02912312
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
12
States / cities
Gilbert, Arizona • San Diego, California • Greeley, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT05652686
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Interventions
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin, Irinotecan (drug), Topotecan
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Transducers of Physical Activity Consortium

NCT03960827
View directory record Official record
Conditions
Physical Activity
Interventions
EE Training, RE Training
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Recruiting Phase 2 Interventional

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

NCT05951777
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Autologous HB-adMSCs, Normal Saline
Biological · Drug
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Recruiting Not applicable Interventional

MOTION Clinical Trial

NCT06843980
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
MISHA Knee System, Non-Surgical Treatment
Device · Other
Lead sponsor
Moximed
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Davis, California • Oceanside, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Active, not recruiting Phase 3 Interventional

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Sibeprenlimab 400 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

NCT05361941
View directory record Official record
Conditions
Periprosthetic Joint Infections
Interventions
EP Granules with Tobramycin, empty voids
Device
Lead sponsor
Elute, Inc.
Industry
Eligibility
22 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Skokie, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 2:08 PM EST
Completed Phase 2 Interventional Results available

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

NCT05254002
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
46
States / cities
Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 15, 2026, 2:08 PM EST